MedTrace Logo

Effect of Intravitreally Administered AIV007 in Subjects With Neovascular Age-Related Macular Degeneration

NCT04422899 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2024-12-27

No results posted yet for this study

Summary

To determine safety, pharmacokinetics, and duration of effect of intravitreally administered AIV007 gel suspension in subjects with neovascular age-related macular degeneration

Conditions

  • Neovascular Age-related Macular Degeneration

Interventions

DRUG

AIV007

intravitreal

Sponsors & Collaborators

  • AiViva BioPharma, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-28
Primary Completion
2021-09-29
Completion
2022-02-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04422899 on ClinicalTrials.gov